DARA BioSciences, Inc.

DARA BioSciences, Inc. (DARA BioSciences), formerly Point therapeutics, Inc. is a development stage pharmaceutical company engaged in the acquisition of therapeutic molecules and medical technologies from third parties, which the company advances its clinical development for later sale to pharmaceutical and biotechnology companies. The company develops and commercializes pharmaceutical products to treat diseases with unmet medical solutions. DARA turned its focus on therapeutic development efforts of small molecules from preclinical development through phase 2 clinical trials. Currently, the company runs two development programs namely, KRN5500 and DB959 for neuropathic pain in cancer patients and, type 2 diabetes respectively. On 12 Feb 2008, DARA completed its merger transaction with Point Therapeutics, Inc., where DP Acquisition Corp. (a wholly owned subsidiary of Point Therapeutics, Inc.) merged into DARA BioSciences, Inc. The company is headquartered in North Carolina, the US.

Street: 
8601 Six Forks Road
City: 
Raleigh
Postcode: 
27615
Federal State : 
United States
WebSite: 
www.darabiosciences.com
Fax: 
1-919-8610239

Company Index Score

Current Index Score Historical Index Score
  • DARA BioSciences, Inc. currently scores 50 % in the index.
  • DARA BioSciences, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • DARA BioSciences, Inc. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets